CRISPR THERAPEUTICS AG— Sankey Diagram

Quarterly mode · period ending 2026-03-31 · SEC EDGAR

ComparingFY2026 (Q1+Q2+Q3+Q4) vs FY2025 (Q1+Q2+Q3+Q4)
Revenue
$4M
↓-89.1% -$34Mvs FY2025 (Q1+Q2+Q3+Q4)
Gross Profit
$4M
↓-89.1% -$34Mvs FY2025 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2026 (Q1+Q2+Q3+Q4)FY2025 (Q1+Q2+Q3+Q4)
Revenue$4M$38M
COGS$0$0
Gross Profit$4M$38M
R&D$281M$307M
SG&A$0$0
D&A$19M$19M
Other OpEx$0$0
Operating Income$0$0
Interest Exp.$0$0
Other Non-Op$0$0
Pretax Income$0$0
Tax$0$0
Net Income$0$0

QuarterCharts · SEC EDGAR data · CRSP · Comparing FY2026 (Q1+Q2+Q3+Q4) vs FY2025 (Q1+Q2+Q3+Q4)